- Home
- HALO vs ICLR Comparison
HALO vs ICLR Comparison
Compare HALO & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HALO | ICLR |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.1B |
| IPO Year | 2001 | 2001 |
Fundamental Metrics
Financial Performance| Metric | HALO | ICLR |
|---|---|---|
| Price | $67.28 | $107.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $78.18 | ★ $194.38 |
| AVG Volume (30 Days) | 1.8M | ★ 3.4M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.56 | N/A |
| Revenue | ★ $151,862,000.00 | N/A |
| Revenue This Year | $28.24 | N/A |
| Revenue Next Year | $12.79 | N/A |
| P/E Ratio | $26.21 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.50 | $66.57 |
| 52 Week High | $82.22 | $211.00 |
Technical Indicators
Market Signals| Indicator | HALO | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 35.07 | 36.39 |
| Support Level | $62.97 | $66.57 |
| Resistance Level | $68.00 | $153.72 |
| Average True Range (ATR) | 2.37 | 5.42 |
| MACD | -0.79 | 3.15 |
| Stochastic Oscillator | 6.69 | 74.62 |
Price Performance
Historical ComparisonAbout HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.